Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A Note from Our New Editor-in-Chief.

Edison P.

Brain Connect. 2019 Oct;9(8):593. doi: 10.1089/brain.2019.29002.ped. No abstract available.

PMID:
31622125
2.

Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects.

Dani M, Wood M, Mizoguchi R, Fan Z, Edginton T, Hinz R, Win Z, Brooks DJ, Edison P.

J Alzheimers Dis. 2019;70(2):455-465. doi: 10.3233/JAD-181168.

PMID:
31256120
3.

A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies.

Perani D, Iaccarino L, Lammertsma AA, Windhorst AD, Edison P, Boellaard R, Hansson O, Nordberg A, Jacobs AH; IMBI Project.

Alzheimers Dement. 2019 Aug;15(8):1081-1103. doi: 10.1016/j.jalz.2019.02.004. Epub 2019 Jun 21.

PMID:
31230910
4.

Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.

Wang YT, Edison P.

Curr Neurol Neurosci Rep. 2019 Jun 6;19(7):45. doi: 10.1007/s11910-019-0962-7. Review.

5.

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).

Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Brooks DJ, Passmore AP, Ballard C, Edison P.

Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x.

6.

Dynamic 11C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis.

Schubert JJ, Veronese M, Marchitelli L, Bodini B, Tonietto M, Stankoff B, Brooks DJ, Bertoldo A, Edison P, Turkheimer FE.

J Nucl Med. 2019 Oct;60(10):1452-1460. doi: 10.2967/jnumed.118.223834. Epub 2019 Mar 8.

PMID:
30850505
7.

Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume.

Femminella GD, Dani M, Wood M, Fan Z, Calsolaro V, Atkinson R, Edginton T, Hinz R, Brooks DJ, Edison P.

Neurology. 2019 Mar 19;92(12):e1331-e1343. doi: 10.1212/WNL.0000000000007133. Epub 2019 Feb 22.

8.

Systematic Analysis and Biomarker Study for Alzheimer's Disease.

Li X, Wang H, Long J, Pan G, He T, Anichtchik O, Belshaw R, Albani D, Edison P, Green EK, Scott J.

Sci Rep. 2018 Nov 26;8(1):17394. doi: 10.1038/s41598-018-35789-3.

9.

In vivo Imaging of Glial Activation in Alzheimer's Disease.

Edison P, Donat CK, Sastre M.

Front Neurol. 2018 Aug 7;9:625. doi: 10.3389/fneur.2018.00625. eCollection 2018. Review.

10.

Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.

Dani M, Wood M, Mizoguchi R, Fan Z, Walker Z, Morgan R, Hinz R, Biju M, Kuruvilla T, Brooks DJ, Edison P.

Brain. 2018 Sep 1;141(9):2740-2754. doi: 10.1093/brain/awy188.

PMID:
30052812
11.

Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?

Femminella GD, Taylor-Davies G, Scott J, Edison P; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(3):981-993. doi: 10.3233/JAD-180365.

PMID:
29966204
12.

Role of Neuroinflammation in the Trajectory of Alzheimer's Disease and in vivo Quantification Using PET.

Edison P, Brooks DJ.

J Alzheimers Dis. 2018;64(s1):S339-S351. doi: 10.3233/JAD-179929. Review.

13.

Erratum to: Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET.

Donat CK, Mirzaei N, Tang SP, Edison P, Sastre M.

Methods Mol Biol. 2018;1750:E1. doi: 10.1007/978-1-4939-7704-8_26. No abstract available.

PMID:
29696592
14.

Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects.

Fan Z, Dani M, Femminella GD, Wood M, Calsolaro V, Veronese M, Turkheimer F, Gentleman S, Brooks DJ, Hinz R, Edison P.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1432-1441. doi: 10.1007/s00259-018-3984-5. Epub 2018 Mar 9.

15.

Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET.

Donat CK, Mirzaei N, Tang SP, Edison P, Sastre M.

Methods Mol Biol. 2018;1750:323-339. doi: 10.1007/978-1-4939-7704-8_22. Erratum in: Methods Mol Biol. 2018;1750:E1.

PMID:
29512083
16.

Reducing radiation hazard opportunities in neonatal unit: quality improvement in radiation safety practices.

Edison P, Chang PS, Toh GH, Lee LN, Sanamandra SK, Shah VA.

BMJ Open Qual. 2017 Oct 21;6(2):e000128. doi: 10.1136/bmjoq-2017-000128. eCollection 2017.

17.

Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.

Femminella GD, Bencivenga L, Petraglia L, Visaggi L, Gioia L, Grieco FV, de Lucia C, Komici K, Corbi G, Edison P, Rengo G, Ferrara N.

J Diabetes Res. 2017;2017:7420796. doi: 10.1155/2017/7420796. Epub 2017 Jun 1. Review.

18.

Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.

Parbo P, Ismail R, Hansen KV, Amidi A, Mårup FH, Gottrup H, Brændgaard H, Eriksson BO, Eskildsen SF, Lund TE, Tietze A, Edison P, Pavese N, Stokholm MG, Borghammer P, Hinz R, Aanerud J, Brooks DJ.

Brain. 2017 Jul 1;140(7):2002-2011. doi: 10.1093/brain/awx120.

PMID:
28575151
19.

Suspected non-Alzheimer's pathology - Is it non-Alzheimer's or non-amyloid?

Dani M, Brooks DJ, Edison P.

Ageing Res Rev. 2017 Jul;36:20-31. doi: 10.1016/j.arr.2017.02.003. Epub 2017 Feb 21. Review.

PMID:
28235659
20.

An early and late peak in microglial activation in Alzheimer's disease trajectory.

Fan Z, Brooks DJ, Okello A, Edison P.

Brain. 2017 Mar 1;140(3):792-803. doi: 10.1093/brain/aww349.

21.

Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein.

Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, Trigg W, Brooks DJ, Hinz R, Edison P.

J Nucl Med. 2016 Nov;57(11):1753-1759. Epub 2016 Jun 3.

22.

Alterations in Glucose Metabolism in Alzheimer's Disease.

Calsolaro V, Edison P.

Recent Pat Endocr Metab Immune Drug Discov. 2016;10(1):31-39. Review.

PMID:
27306508
23.

Neuroinflammation in Alzheimer's disease: Current evidence and future directions.

Calsolaro V, Edison P.

Alzheimers Dement. 2016 Jun;12(6):719-32. doi: 10.1016/j.jalz.2016.02.010. Epub 2016 May 11. Review.

PMID:
27179961
24.

Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?

Femminella GD, Ninan S, Atkinson R, Fan Z, Brooks DJ, Edison P.

J Alzheimers Dis. 2016;51(4):1275-89. doi: 10.3233/JAD-150827.

PMID:
27060942
25.

Amyloid pathology and axonal injury after brain trauma.

Scott G, Ramlackhansingh AF, Edison P, Hellyer P, Cole J, Veronese M, Leech R, Greenwood RJ, Turkheimer FE, Gentleman SM, Heckemann RA, Matthews PM, Brooks DJ, Sharp DJ.

Neurology. 2016 Mar 1;86(9):821-8. doi: 10.1212/WNL.0000000000002413. Epub 2016 Feb 3.

26.

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

Calsolaro V, Edison P.

CNS Drugs. 2015 Dec;29(12):1023-39. doi: 10.1007/s40263-015-0301-8. Review.

PMID:
26666230
27.

Tau imaging in neurodegenerative diseases.

Dani M, Brooks DJ, Edison P.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1139-50. doi: 10.1007/s00259-015-3231-2. Epub 2015 Nov 16. Review.

28.

Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.

Fan Z, Okello AA, Brooks DJ, Edison P.

Brain. 2015 Dec;138(Pt 12):3685-98. doi: 10.1093/brain/awv288. Epub 2015 Oct 27.

29.

Imaging biomarkers in tauopathies.

Dani M, Edison P, Brooks DJ.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S26-8. doi: 10.1016/j.parkreldis.2015.08.011. Epub 2015 Aug 14. Review.

PMID:
26299160
30.

Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?

Fan Z, Harold D, Pasqualetti G, Williams J, Brooks DJ, Edison P.

J Nucl Med. 2015 May;56(5):707-13. doi: 10.2967/jnumed.114.149443. Epub 2015 Apr 3.

31.

The role of neuroinflammation in dementias.

Pasqualetti G, Brooks DJ, Edison P.

Curr Neurol Neurosci Rep. 2015 Apr;15(4):17. doi: 10.1007/s11910-015-0531-7. Review.

PMID:
25716012
32.

Carcinoid-associated encephalopathy.

Femminella GD, Kenny LM, Sinha A, Amlani S, Edison P.

J Clin Gastroenterol. 2015 Apr;49(4):353-4. doi: 10.1097/MCG.0000000000000272. No abstract available.

33.

Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions.

Varley J, Brooks DJ, Edison P.

Alzheimers Dement. 2015 Sep;11(9):1110-20. doi: 10.1016/j.jalz.2014.08.105. Epub 2014 Nov 15. Review.

PMID:
25449529
34.

Cortical hypermetabolism in MCI subjects: a compensatory mechanism?

Ashraf A, Fan Z, Brooks DJ, Edison P.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):447-58. doi: 10.1007/s00259-014-2919-z. Epub 2014 Sep 30.

PMID:
25267349
35.

Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.

Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, Brooks DJ, Edison P.

Alzheimers Dement. 2015 Jun;11(6):608-21.e7. doi: 10.1016/j.jalz.2014.06.016. Epub 2014 Sep 16.

PMID:
25239737
36.

Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging.

Femminella GD, Edison P.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S55-61. doi: 10.1016/j.jalz.2013.12.012. Review.

PMID:
24529526
37.

The emerging agenda of stratified medicine in neurology.

Matthews PM, Edison P, Geraghty OC, Johnson MR.

Nat Rev Neurol. 2014 Jan;10(1):15-26. doi: 10.1038/nrneurol.2013.245. Epub 2013 Dec 10. Review.

PMID:
24323053
38.

Reference region automatic extraction in dynamic [(11)C]PIB.

Ikoma Y, Edison P, Ramlackhansingh A, Brooks DJ, Turkheimer FE.

J Cereb Blood Flow Metab. 2013 Nov;33(11):1725-31. doi: 10.1038/jcbfm.2013.133. Epub 2013 Aug 7.

39.

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.

Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, Walker Z, Turkheimer FE, Brooks DJ.

Neuropsychopharmacology. 2013 May;38(6):938-49. doi: 10.1038/npp.2012.255. Epub 2012 Dec 6.

40.

Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.

Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, Brooks DJ, Hinz R.

Neuroimage. 2013 Apr 15;70:423-33. doi: 10.1016/j.neuroimage.2012.12.014. Epub 2012 Dec 20.

PMID:
23261639
41.

Drug repositioning for Alzheimer's disease.

Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, Kearns I, Kehoe P, Mudher A, Passmore A, Shepherd N, Walsh F, Ballard C.

Nat Rev Drug Discov. 2012 Nov;11(11):833-46. doi: 10.1038/nrd3869. Review.

PMID:
23123941
42.

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.

Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, Perani D, Forsberg A, Långström B, Scheinin N, Karrasch M, Någren K, Grimmer T, Miederer I, Edison P, Okello A, Van Laere K, Nelissen N, Vandenbulcke M, Garibotto V, Almkvist O, Kalbe E, Hinz R, Herholz K.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):104-14. doi: 10.1007/s00259-012-2237-2. Epub 2012 Sep 8.

43.

Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?

Edison P, Hinz R, Ramlackhansingh A, Thomas J, Gelosa G, Archer HA, Turkheimer FE, Brooks DJ.

Neuroimage. 2012 Apr 15;60(3):1716-23. doi: 10.1016/j.neuroimage.2012.01.099. Epub 2012 Jan 27.

44.

Improving recruitment of older people to research through good practice.

McMurdo ME, Roberts H, Parker S, Wyatt N, May H, Goodman C, Jackson S, Gladman J, O'Mahony S, Ali K, Dickinson E, Edison P, Dyer C; Age and Ageing Specialty Group, NIHR, Comprehensive Clinical Research Network.

Age Ageing. 2011 Nov;40(6):659-65. doi: 10.1093/ageing/afr115. Epub 2011 Sep 11. Review.

PMID:
21911335
45.

Technical aspects of amyloid imaging for Alzheimer's disease.

Edison P, Hinz R, Brooks DJ.

Alzheimers Res Ther. 2011 Aug 31;3(4):25. doi: 10.1186/alzrt87.

46.

11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease.

Hyare H, Ramlackhansingh A, Gelosa G, Edison P, Rudge P, Brandner S, Brooks DJ, Collinge J, Mead S.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):340-1. doi: 10.1136/jnnp.2010.233692. Epub 2011 Apr 8. No abstract available.

PMID:
21478204
47.

Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers.

Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN.

Brain. 2011 Jan;134(Pt 1):293-300. doi: 10.1093/brain/awq310. Epub 2010 Nov 16.

PMID:
21084313
48.

(11)C-PIB PET in subjective cognitive impairment.

Rodda J, Okello A, Edison P, Dannhauser T, Brooks DJ, Walker Z.

Eur Psychiatry. 2010 Mar;25(2):123-5. doi: 10.1016/j.eurpsy.2009.07.011. Epub 2009 Nov 18.

PMID:
19926266
49.

Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility.

Edison P, Brooks DJ, Turkheimer FE, Archer HA, Hinz R.

Neuroimage. 2009 Nov 1;48(2):329-38. doi: 10.1016/j.neuroimage.2009.06.079. Epub 2009 Jul 8.

PMID:
19591948
50.

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ.

Neurology. 2009 Sep 8;73(10):754-60. doi: 10.1212/WNL.0b013e3181b23564. Epub 2009 Jul 8.

Supplemental Content

Loading ...
Support Center